Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA), for drug-medical device combination products at its injectable facility in Nagpur, India. The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
